Editor's Note: In 2023, significant progress has been made in the field of breast cancer research. Dr. Zefei Jiang from The Fifth Medical Center of Chinese PLA General Hospital shared his insights and research findings at several important conferences. This article delves into Professor Jiang's speeches, exploring the key advancements in breast cancer treatment in 2023.Designing Clinical Trials for Breast Cancer
In the column “Tribute to Classics—Reading Classics and Continuing the Legend,” Dr. Zefei Jiang, along with other experts, discussed the skills and experiences in designing clinical trials for breast cancer. He emphasized that well-designed clinical research significantly promotes the successful launch of new drugs. Professor Jiang specifically mentioned that the treatment strategies for HER2-low breast cancer are continuously advancing, and the emergence of T-DXd has brought revolutionary results for patients with HER2-low expression.
Differences in Breast Cancer Treatment Between China and the United States
Dr. Zefei Jiang’s team published a study in the Journal of the American Medical Association (JAMA) Network Open, analyzing the differences in early breast cancer treatment between China and the United States. The study found that Chinese breast cancer patients are diagnosed at a younger median age and at a later stage of the disease, but the treatment gap for HER2-positive breast cancer is gradually narrowing. Professor Jiang pointed out that with the improvement of academic standards and comprehensive national strength in China, targeted therapy for HER2-positive breast cancer has made significant progress.
Multidimensional Progress in Breast Cancer Treatment
Dr. Zefei Jiang has emphasized the multidimensional progress in breast cancer treatment on multiple occasions. He mentioned that the treatment of breast cancer patients should not only aim to extend survival but also improve quality of life. He advocated optimizing treatment methods, such as switching from intravenous injections to oral or subcutaneous administrations, to enhance patient adherence to treatment. Additionally, he emphasized that managing breast cancer as a chronic disease requires the joint efforts of doctors, nurses, and patients’ families, as well as the use of artificial intelligence for individual case management to remind patients to continue their treatment.
Conclusion
Dr. Zefei Jiang’s research findings and insights not only provide new strategies for breast cancer treatment but also indicate future research directions. Through continuous clinical research and international cooperation, breast cancer treatment will become more precise and effective. Professor Jiang’s in-depth analysis and forward-thinking perspectives paint a bright future for breast cancer treatment.
Professor Zefei Jiang
Director of Oncology, Cancer Center of the General Hospital of the People’s Liberation Army Deputy Chairman of the Youth Expert Committee, Chinese Society of Clinical Oncology (CSCO) Member and Secretary-General, Oncology Expert Committee, Capacity Building and Continuing Education Center, National Health Commission Standing Member, Patient Education Expert Committee and Member, Breast Cancer Expert Committee, CSCO Member, Breast Cancer Professional Committee, Chinese Anti-Cancer Association (CBCS) Standing Member, Breast Disease Branch, Chinese Medical Health International Exchange Promotion Association Deputy Leader, Breast Cancer Diagnosis and Treatment Technology Promotion Group, China National Health Association Member, Breast Professional Committee, Chinese Research Hospital Association Deputy Chairman, Breast Health Science Popularization Expert Committee, Shanghai Science Popularization Volunteers Association Standing Member, Breast Cancer Expert Committee and Cancer Rehabilitation and Palliative Care Expert Committee, Shanghai Anti-Cancer Association Member, Breast Cancer Group, Surgery Branch, Shanghai Medical Association Class Leader, First Session of the Medical Star Plan, Shanghai Health Development Foundation Editorial Board Member of CA Chinese Edition and Chinese Medical Forum Oncology Edition Review Expert for Frontiers in Oncology, JNCC Youth Editorial Board Member, Chinese Journal of Oncology
